Interventional Therapies for Heart Failure
Interventional therapies for heart failure are growing rapidly and represent a new frontier in our field. This issue is our first to focus on understanding more about interventional treatment of heart failure.
In our first feature article, Scott M. Lilly, MD, and Daniel Burkhoff, MD, describe the potential advantages and drawbacks of three novel devices being developed for the treatment of left atrial decompression in heart failure. Next, Sahil Khera, MD, and Srihari S. Naidu, MD, evaluate the function and position of hemodynamic support devices in treating emergent cardiogenic shock and cases of high-risk percutaneous coronary intervention (PCI). David M. Shavelle, MD, then offers an in-depth review of the pre- and postprocedure technical considerations for implanting the CardioMEMS heart failure sensor (Abbott Vascular, formerly St. Jude Medical).
Our coverage of heart failure wraps up with an expert panel weighing in on the role that mitral repair has in the future of treating heart failure. Panelists include William Weir, MD; Stephen F. Bolling, MD; Brian Whisenant, MD; Nyal Borges, MD; Samir Kapadia, MD; Muath Bishawi, MD; and Donald D. Glower Jr, MD.
We have also curated several articles discussing concepts in the use of radial access. Senthil K. Elangovan, MRCP; Alex J. Chase, PhD; Adrian Ionescu, MD; and Daniel R. Obaid, PhD, provide insight on difficult radial anatomy that can be encountered during PCI and highlight how the use of balloon-assisted tracking can alleviate this challenge.
M. Imran Aslam, MD, and Rani K. Hasan, MD, propose that after a slow adoption of radial access for coronary angiography in the United States, it’s time to accept the positive data outcomes for radial access in coronary intervention and embrace a radial-first approach. Zoltan G. Turi, MD, then offers a look at the pros and cons of vascular closure devices and the potential that these devices have in mitigating the shortcomings of femoral access compared with radial access.
In an update on structural disease, Dominik M. Wiktor, MD, and John D. Carroll, MD, evaluate data from the RESPECT (long-term), REDUCE, and CLOSE trials and discuss how these data may impact the treatment of cryptogenic stroke with patent foramen ovale closure.
In our Today’s Practice section, William W. O’Neill, MD, and Michael J. Lim, MD, explain the background of and current experience with the Cardiogenic Shock Initiative algorithm at both the regional and national levels.
The FAME 2 and ORBITA clinical trials have been a hot topic of discussion since the findings were presented at the 29th annual Transcatheter Cardiovascular Therapeutics conference. William Fearon, MD, and Ajay J. Kirtane, MD, discuss the impact these study findings may have on patients with coronary artery disease undergoing PCI.
Our Coding & Reimbursement section provides crucial financial insight for cardiovascular care by offering tips on how hospitals can improve their heart programs and, in the process, find money being left on the table.
Finally, in our featured interview, Subhash Banerjee, MD, shares the current status of both the CPRS-CKD study and the PREMIER phase 2 trial, as well as highlights from the recent Cardiovascular Innovations meeting.
We hope these reviews are timely, relevant, and interesting and will serve to synthesize the vast and ever-expanding interventional literature.
Ted E. Feldman, MD, MSCAI, FACC, FESC
Chief Medical Editor